Karen Anderson Sells 41,076 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Key Points

• Karen Anderson sold 41,076 shares on March 26 at an average price of $30.12 for proceeds of $1,237,209.12, leaving her with 62,085 shares — a 39.82% reduction in her position.
• Institutional ownership is high at 82.01%, with large recent purchases including Avoro Capital (added ~5.8M shares) and EcoR1 Capital (added ~2.565M shares), indicating significant institutional accumulation.
• Analysts are largely positive: the consensus rating is "Buy" with an average target of $39.80, and several firms have raised targets notably (Oppenheimer to $62, B. Riley to $42).

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Karen Anderson sold 41,076 shares of the stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the transaction, the insider owned 62,085 shares of the company's stock, valued at $1,870,000.20. This trade represents a 39.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $28.70 on Friday. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $30.58. The company has a market cap of $4.19 billion, a PE ratio of -15.68 and a beta of 1.55. The stock's 50-day moving average price is $25.85 and its two-hundred day moving average price is $25.04.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC boosted its holdings in shares of Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company's stock worth $262,096,000 after purchasing an additional 5,808,080 shares during the period. EcoR1 Capital LLC grew its position in Centessa Pharmaceuticals by 466.4% during the fourth quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company's stock valued at $77,906,000 after purchasing an additional 2,565,000 shares in the last quarter. Braidwell LP acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at approximately $54,730,000. Federated Hermes Inc. acquired a new position in Centessa Pharmaceuticals in the 3rd quarter valued at approximately $42,429,000. Finally, Maverick Capital Ltd. purchased a new stake in Centessa Pharmaceuticals in the 4th quarter worth approximately $41,110,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on CNTA. Weiss Ratings restated a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Piper Sandler reaffirmed an "overweight" rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. TD Cowen reiterated a "buy" rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. B. Riley Financial boosted their target price on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a "buy" rating in a research note on Monday, December 1st. Finally, Oppenheimer increased their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an "outperform" rating in a report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $39.80.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.